Serenity Pharmaceuticals LLC – Trademark Portfolio

Entity Type: 16

Serenity Pharmaceuticals LLC holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The owner is based in Mississauga, Ontario.

Suite 205

7025 Langer Drive

Mississauga, Ontario L5N0E8 , CA

17 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NOCUVANT
NOCUVANT
Abandoned 2021
NOCTIVA
NOCTIVA
Abandoned 2021
REMIO
REMIO
Abandoned 2020
NOZURIA
NOZURIA
Abandoned 2020
REMNOCT
REMNOCT
Abandoned 2019
RELISERA
RELISERA
Abandoned 2019
NOZURIA
NOZURIA
Abandoned 2016
REMIO
REMIO
Abandoned 2016
RESTNOCT
RESTNOCT
Abandoned 2016
PAZINOCT
PAZINOCT
Abandoned 2016
REMNOCT
REMNOCT
Abandoned 2016
RELISERA
RELISERA
Abandoned 2016
PACSERA
PACSERA
Abandoned 2014
RELISERA
RELISERA
Abandoned 2011
PACSERA
PACSERA
Abandoned 2011
PAZINOCT
PAZINOCT
Abandoned 2011
REMNOCT
REMNOCT
Abandoned 2011

Trademark Classifications

Serenity Pharmaceuticals LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (17 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Serenity Pharmaceuticals LLC have?

Serenity Pharmaceuticals LLC has 17 U.S. trademarks filed with the USPTO.

What trademark classes does Serenity Pharmaceuticals LLC file in?

Serenity Pharmaceuticals LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is Serenity Pharmaceuticals LLC's trademark registration success rate?

Serenity Pharmaceuticals LLC has a 0% trademark registration rate, with 0 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.